The therapeutic effects of PJ34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation.
about
Txk, a member of the non-receptor tyrosine kinase of the Tec family, forms a complex with poly(ADP-ribose) polymerase 1 and elongation factor 1alpha and regulates interferon-gamma gene transcription in Th1 cellsMultiple sclerosis: molecular mechanisms and therapeutic opportunitiesStructural Basis for the Identification of the N-Terminal Domain of Coronavirus Nucleocapsid Protein as an Antiviral TargetUnderstanding specific functions of PARP-2: new lessons for cancer therapyThe anti-cancer agent SU4312 unexpectedly protects against MPP(+) -induced neurotoxicity via selective and direct inhibition of neuronal NOSChronic PARP-1 inhibition reduces carotid vessel remodeling and oxidative damage of the dorsal hippocampus in spontaneously hypertensive rats.Therapeutic effect of a poly(ADP-ribose) polymerase-1 inhibitor on experimental arthritis by downregulating inflammation and Th1 response.Mice with different susceptibility to Japanese encephalitis virus infection show selective neutralizing antibody response and myeloid cell infectivityInhibiting poly(ADP-ribose) polymerase: a potential therapy against oligodendrocyte death.Anti-inflammatory effects of PJ34, a poly(ADP-ribose) polymerase inhibitor, in transient focal cerebral ischemia in miceFrataxin Deficiency Promotes Excess Microglial DNA Damage and Inflammation that Is Rescued by PJ34Poly(ADP-ribose) polymerase 2 contributes to neuroinflammation and neurological dysfunction in mouse experimental autoimmune encephalomyelitisTherapeutic applications of PARP inhibitors: anticancer therapy and beyondRole of Txk, a member of the Tec family of tyrosine kinases, in immune-inflammatory diseases.The importance of NAD in multiple sclerosisPARP-1 deficiency increases the severity of disease in a mouse model of multiple sclerosis.Long-term suppression of EAE relapses by pharmacological impairment of epitope spreading.Beyond DNA repair, the immunological role of PARP-1 and its siblings.A further TWEAK to multiple sclerosis pathophysiology.Synergistic inhibition of PARP-1 and NF-κB signaling downregulates immune response against recombinant AAV2 vectors during hepatic gene therapy.Poly-ADP-ribosyl polymerase-14 promotes T helper 17 and follicular T helper development.Contribution of poly(ADP-ribose) polymerase to postischemic blood-brain barrier damage in rats.Effects of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide on blood-brain barrier and dopaminergic neurons of rats with lipopolysaccharide-induced Parkinson's disease.PARP1 depletion improves mitochondrial and heart function in Chagas disease: Effects on POLG dependent mtDNA maintenance.
P2860
Q24337273-72F391FA-3098-40A4-8C65-B732F7E50DC5Q27023735-4E7BF758-F6F6-4EF6-A66F-749EF81E77A6Q27681874-7629A414-7147-4766-A251-65F03E106BBCQ28067486-9CBC922F-CC7B-48FD-978C-B09FB7DB2511Q28583196-D2E78924-B188-4C9E-A3C7-750C0F5FD39BQ30359347-9737B300-61BB-4CCB-A9EC-6C0049AEBA9DQ33304428-093B4462-64E1-4EFF-AE3E-A2C748F62F2CQ34031442-596E9AE0-5E26-4E19-9DC1-374CB855AFC4Q34242985-3782AB5C-E623-493E-B992-9CE0FF00EDF0Q35119919-07883426-4F6F-4768-AC5C-E44BA581B40BQ35949121-246ABAAD-4B1C-476C-8435-A1F53F6264FCQ36808573-B8C7AB45-1F10-49F1-B1DC-323139F1C34AQ36853236-706F7119-C45F-4328-9323-8504FD35CF78Q37008658-750A50F0-3E8A-438A-889F-BF7620BCF8B2Q37118012-3C116FEB-EC87-4037-B989-D3054157CAC4Q37377750-468A8519-10C3-400D-8054-90F8D9D4679AQ37637777-0F6A21BD-8C75-4B2F-B66A-832F4D291CDEQ38089268-CECAA775-2BA0-45B7-8919-C571585FF0B9Q38123074-A90AF18A-63F2-4C2A-B9AB-C104E223EFB9Q40458807-84F1C4DE-7AFF-496D-A5B7-E893D1631EC4Q41535001-F8A4E3B0-0731-4DF4-A1AF-73EEE5F4EEC4Q48314697-17DEA0FD-8B57-4654-920A-ECA170A525FCQ48859939-F127CC11-B301-4C97-BD0D-AB7E4DDAB7F8Q55416701-6BF49799-7488-4FAA-B124-53638E7FD250
P2860
The therapeutic effects of PJ34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
The therapeutic effects of PJ3 ...... ociated with immunomodulation.
@en
The therapeutic effects of PJ3 ...... ociated with immunomodulation.
@nl
type
label
The therapeutic effects of PJ3 ...... ociated with immunomodulation.
@en
The therapeutic effects of PJ3 ...... ociated with immunomodulation.
@nl
prefLabel
The therapeutic effects of PJ3 ...... ociated with immunomodulation.
@en
The therapeutic effects of PJ3 ...... ociated with immunomodulation.
@nl
P2093
P356
P1476
The therapeutic effects of PJ3 ...... sociated with immunomodulation
@en
P2093
Csaba Szabó
Gwen S Scott
Jon G Mabley
Marzena J Fabis
Rhonda B Kean
Tatiana Mikheeva
P304
P356
10.1124/JPET.103.063214
P407
P577
2004-05-24T00:00:00Z